NCT00089440

Brief Summary

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
17

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jun 2004

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 5, 2004

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 6, 2004

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2005

Completed
Last Updated

January 11, 2017

Status Verified

July 1, 2005

First QC Date

August 5, 2004

Last Update Submit

January 10, 2017

Conditions

Amphetamine-Related Disorders

Outcome Measures

Primary Outcomes (2)

  • Adverse effect measures

  • pharmacokinetic assessment

Interventions

AripiprazoleDRUG

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

You may not qualify if:

  • Please contact the site for more information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

UCLA Integrated Substance Abuse Program

Los Angeles, California, 90024, United States

Location

New York University, School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Amphetamine-Related Disorders

Interventions

Aripiprazole

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Thomas Newton, M.D.

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

August 5, 2004

First Posted

August 6, 2004

Study Start

June 1, 2004

Study Completion

March 1, 2005

Last Updated

January 11, 2017

Record last verified: 2005-07

Locations

US(2)